Overview

A Clinical Gene Therapy Study with Hematopoietic Stem Cells for the Treatment, with Single Dose of Temferon, of Patients Suffering from Metastatic Renal Cell Carcinoma

Status:
RECRUITING

Trial end date:
2026-09-30

Target enrollment:

Participant gender:

Summary

This is an open label, single-centre phase 1/2 study involving a single dose of Temferon, an investigational Advanced Therapy Medicinal Product (ATMP), to treat patients with metastatic clear cell renal cell carcinoma (RCC) with evidence of disease progression following at least two lines of standard of care (SoC) treatments.

Phase:

PHASE1

Details

Lead Sponsor:

Genenta Science

Collaborators:

Alira Health
Arithmos srl
Ospedale San Raffaele

Treatments:

cabozantinib
pembrolizumab